SCHAFER CAROL 4

What Happened
Carol Schafer, a director of Kura Oncology, received a grant/award of 35,000 derivative shares (reported as an option award) on June 4, 2026. The filing reports a price of $0.00 for the award, so the immediate reported value is $0; the instrument is described as an option that vests in full one year after the grant date. This was a grant/award (not a purchase or sale).

Key Details

• Transaction date: 2026-06-04 (filed same day)
• Transaction type: Grant/Award (derivative) — code A
• Amount: 35,000 shares; reported price $0.00; reported immediate value $0
• Vesting: Vests in full on the one-year anniversary of the grant (footnote F1)
• Shares owned after transaction: Not specified in the filing
• Timeliness: Filed timely (no late filing indicated)

Context
This is a typical director compensation/retention award rather than an open-market buy or sale. As a derivative option award, it does not represent an immediate cash purchase or sale; value realization would depend on future vesting and any exercise terms. Such grants are common for board members and do not by themselves indicate insider buying or selling sentiment.